Coronavirus disease 2019 (COVID-19) is a fatal and fast-spreading viral infection. To date, the number of COVID-19 patients worldwide has crossed over six million with over three hundred and seventy thousand deaths (according to the data from World Health Organization; updated on 2 June 2020). Although COVID-19 can be rapidly diagnosed, efficient clinical treatment of COVID-19 remains unavailable, resulting in high fatality. Some clinical trials have identified vitamin C (VC) as a potent compound pneumonia management. In addition, glycyrrhizic acid (GA) is clinically as an anti-inflammatory medicine against pneumonia-induced inflammatory stress. We hypothesized that the combination of VC and GA is a potential option for treating COVID-19.

中文翻译：

---

维生素C联合甘草酸抗COVID-19的综合药理机制：生物信息学分析结果

2019 年冠状病毒病 (COVID-19) 是一种致命且快速传播的病毒感染。迄今为止，全球 COVID-19 患者人数已超过 600 万，死亡人数超过 37 万人（根据世界卫生组织的数据；2020 年 6 月 2 日更新）。尽管可以快速诊断出 COVID-19，但仍无法对 COVID-19 进行有效的临床治疗，导致死亡率很高。一些临床试验已确定维生素 C (VC) 是一种有效的复合肺炎治疗方法。此外，甘草酸（GA）在临床上被用作对抗肺炎引起的炎症应激的抗炎药物。我们假设 VC 和 GA 的组合是治疗 COVID-19 的潜在选择。